在2026年通用产品竞争之前,诺沃诺迪斯克在中国两个省份降低了Wegovy的价格. Novo Nordisk cut Wegovy prices in two Chinese provinces ahead of 2026 generic competition.

新诺迪斯克省削减了中国云南省和四川省肥胖药物Wegovy的价格清单,根据当地采购当局的决定,将最高剂量分别削减近一半至987.48元和每月1,284.36元。 Novo Nordisk has slashed the list prices of its obesity drug Wegovy in China’s Yunnan and Sichuan provinces, cutting the highest dosages by nearly half to 987.48 yuan and 1,284.36 yuan per month, respectively, following decisions by local procurement authorities. 这一举动是在2026年西马格卢提德专利到期后预计的仿制药竞争之前进行的,中国公司如CSPC和杭州吉元开发生物仿制药. The move comes ahead of generic competition expected after the semaglutide patent expires in 2026, with Chinese firms like CSPC and Hangzhou Jiuyuan developing biosimilars. 减价是继印度类似减价之后进行的,目的是维持在迅速增长的肥胖症治疗市场中的市场份额。 The price cuts follow a similar reduction in India and aim to maintain market share in a rapidly growing obesity treatment market.